Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study

BMC Pharmacology & Toxicology
Monica DanialAmer Hayat Khan

Abstract

Accurate identification and routine preventive practices are crucial steps in lessening the incidence of medications and patients related adverse drug reactions (ADRs). Three years retrospective study was conducted among chronic kidney disease (CKD) patients at multi-wards in a tertiary healthcare center. Data collected included demographic characteristics, physical examination results, comorbid conditions, laboratory tests and medications taken. Only medication prescribed during the hospital stay were considered in this study. From this study only one ADR incident was definitely preventable and majority of other ADRs (88.3%) were possibly preventable. Type of renal replacement therapy (p = 0.023) and stages of renal function (p = 0.002) were significantly associated with survivability of the hospitalized CKD patients after ADRs. Highest percentage of mortality based on categories were 50-59 years (20.0%), male (16.3%), Indian ethnicity (23.7%), obese (15.0%), smoking (17.1%), consumes alcohol (17.4%), conservative management of renal disease (19.5%) and renal function of < 15 mL/min/1.73m2. Overall survivability using Kaplan-Meier analysis reported a significant difference of 18-day survival rate between patients undergoing he...Continue Reading

References

Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
May 23, 1998·BMJ : British Medical Journal·M PirmohamedB K Park
Apr 29, 1998·JAMA : the Journal of the American Medical Association·J LazarouP N Corey
May 12, 2000·Journal of the American College of Cardiology·J S GottdienerR C Boineau
Nov 10, 2000·Lancet·I R Edwards, J K Aronson
Jul 18, 2001·Internal Medicine Journal·M ChanJ H Vial
Jan 1, 1964·Annals of Internal Medicine·E M SCHIMMEL
Dec 18, 2003·British Journal of Clinical Pharmacology·A A Mangoni, S H D Jackson
Jul 3, 2004·BMJ : British Medical Journal·Munir PirmohamedAlasdair M Breckenridge
Apr 14, 2005·European Journal of Clinical Pharmacology·Yannick ArimoneFrançoise Haramburu
May 16, 2006·Journal of the American Geriatrics Society·Linda F FriedAnne B Newman
Jun 29, 2006·British Journal of Clinical Pharmacology·R L HowardM Pirmohamed
May 25, 2007·Fundamental & Clinical Pharmacology·Sarah N HilmerDavid G Le Couteur
Jun 27, 2008·Journal of the American Medical Informatics Association : JAMIA·Elske AmmenwerthUwe Siebert
Nov 18, 2008·European Journal of Internal Medicine·Alexandra AlexopoulouAthanasios J Archimandritis
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Dec 19, 2009·Handbook of Experimental Pharmacology·Jack A HinsonLaura P James
Mar 16, 2011·Journal of Biomedicine & Biotechnology·Offie P SoldinDonald R Mattison
Apr 5, 2011·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·C Barrett BowlingRichard M Allman
Nov 25, 2011·The New England Journal of Medicine·Daniel S BudnitzChesley L Richards
Jan 19, 2012·The Annals of Pharmacotherapy·Greene ShepherdDianne Williams May
May 10, 2012·JAMA : the Journal of the American Medical Association·Kunihiro MatsushitaUNKNOWN Chronic Kidney Disease Prognosis Consortium
Oct 9, 2012·Current Opinion in Nephrology and Hypertension·Claudio RigattoNavdeep Tangri
Nov 1, 2012·JAMA : the Journal of the American Medical Association·Stein I HallanUNKNOWN Chronic Kidney Disease Prognosis Consortium
Apr 10, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Morgan E GramsJosef Coresh
Apr 17, 2013·British Journal of Clinical Pharmacology·Antje NeubertManfred Criegee-Rieck
Apr 17, 2013·Annals of Internal Medicine·Navdeep TangriAndrew S Levey
Aug 21, 2013·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Lateef M KhanOmar I Saadah
Dec 21, 2014·Journal of the American Society of Nephrology : JASN·Li FanLesley A Inker
Jun 7, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Edward M DoyleMiles D Witham
Aug 20, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Lesley A InkerMark J Sarnak
Feb 3, 2016·Therapeutic Advances in Drug Safety·Amanda Hanora Lavan, Paul Gallagher
Jun 23, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Thamir M Alshammari
Jun 23, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Lateef M KhanAhmed S Ali
Aug 4, 2016·Methods : a Companion to Methods in Enzymology·Yuxiang TanMei Liu
Oct 19, 2016·Circulation·Barbara S WigginsUNKNOWN American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; C

❮ Previous
Next ❯

Citations

Sep 11, 2019·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Yijian ZhangBin Pi
Jul 3, 2020·Clinical Journal of the American Society of Nephrology : CJASN·Solène M LavilleUNKNOWN Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.